echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clin Trans Gastroenterology: Pouch-anal ileal anastomosis (IPAA) treatment of ulcerative colitis is associated with severe decline in quality of life

    Clin Trans Gastroenterology: Pouch-anal ileal anastomosis (IPAA) treatment of ulcerative colitis is associated with severe decline in quality of life

    • Last Update: 2021-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Approximately 10-15% of medsci.
    cn/course/search.
    do?w=%E6%BA%83%E7%96%A1%E6%80%A7%E7%BB%93%E8%82%A0%E7%82%8E">ulcerative colitis (UC) patients require ileal pouch anal anastomosis (IPAA) or proctocolectomy (TPC).
    This operation is usually performed in two or three phases.
    Unfortunately, patients often experience postoperative complications of intestinal fistula or bowel incontinence
    .
    Symptoms of pouch inflammation after IPAA, such as urinary urgency and pain, are related to depression, fatigue, and decreased quality of life.
    The purpose of this study is to compare IPAA-treated UC patients with the decline in the quality of life of drug-treated UC patients, and to determine predictors of disability.

    Approximately 10-15% of medsci.
    cn/course/search.
    do?w=%E6%BA%83%E7%96%A1%E6%80%A7%E7%BB%93%E8%82%A0%E7%82%8E">ulcerative colitis (UC) patients require ileal pouch anal anastomosis (IPAA) or proctocolectomy (TPC).
    This operation is usually performed in two or three phases.
    Unfortunately, patients often experience postoperative intestinal fistula or complications of fecal incontinence,
    medsci.
    cn/course/search.
    do?w=%E6%BA%83%E7%96%A1%E6%80%A7%E7%BB%93%E8%82%A0%E7%82%8E">ulcerative colitis

     


    This study is a multi-center cross-sectional study.
    The researchers recruited UC patients who had undergone medication or surgery to enter the study, and then evaluated the Inflammatory Bowel Disease Disability Index (IBD-DI) for eligible patients.
    The risk factors of moderate to severe disability (IBD-DI≥35) in UC patients were evaluated in univariate and multivariate models.

     


    A total of 94 IPAA patients and 128 drug-treated UC patients completed the IBD-DI assessment.
    Among UC patients undergoing IPAA and medication, 35 (37.
    2%) and 30 (23.
    4%) had moderate to severe disability, respectively.
    Compared with drug-treated UC patients, IPAA patients had a significantly higher IBD-DI score (29.
    8 vs 17.
    9, p<0.
    001).
    When stratified by disease activity, compared with patients with active UC, patients with active IPAA disease had a significantly higher median IBD-DI (44.
    2 vs 30.
    4, p = 0.
    01).
    The moderate to severe disability of IPAA patients is related to women, disease activity and whether they have medical insurance.

    Figure: The impact of IPPA patients' disability

          This study confirmed that the disability score of UC patients who received IPAA treatment was higher than that of UC patients who received drug treatment.
    Female sex and disease activity are risk factors for severe disability in UC patients treated with IPAA.

      This study confirmed that the disability score of UC patients who received IPAA treatment was higher than that of UC patients who received drug treatment.
    Female sex and disease activity are risk factors for severe disability in UC patients treated with IPAA.

     

     

    Original source:

    Maia Kayal.
    Et al.
    Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability.
    Clinical and Translational Gastroenterology.
    2021 .

    Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.